Financial Performance & Outlook - ARIKAYCE worldwide sales reached $92.8 million in Q1 2025, a 22.9% increase compared to $75.5 million in Q1 2024[47] - The company reiterates its 2025 ARIKAYCE revenue guidance of $405 to $425 million[57] - The company had approximately $1.2 billion in cash, cash equivalents, and marketable securities as of March 31, 2025[59] - The company called remaining convertible debt of approximately $570 million, expecting conversion to lower ongoing interest expense and reduce outstanding debt[61] Clinical Program Updates - Brensocatib's FDA review is on track, with a PDUFA target action date of August 12th for potential U.S approval[16] - Phase 3 ASPEN results for Brensocatib in Bronchiectasis were published in NEJM[28] - Phase 2b BiRCh trial for Brensocatib in CRSsNP enrolled 288 patients, with topline readout expected by YE:25[28] - Phase 2b PAH trial topline readout for TPIP is expected in June 2025, with a potential Phase 3 trial initiation in 2H:25[37, 39] - Phase 3 ENCORE trial for ARIKAYCE is progressing on schedule, with topline readout expected in 1H:26[46, 48] Market Engagement - Approximately 53,000 patients have engaged in a high-value action on SpeakUpInBronchiectasis.com[26, 27]
Insmed(INSM) - 2025 Q1 - Earnings Call Presentation